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0.377 QALYs (95% CI: -0.227 to 0.754) and cost savings of € 264 (95% CI: -€ 1,879 to € 
2,768).. At a willingness-to-pay threshold of € 30,000 per QALY gained, SAXA strategy 
had an 82% probability to be cost-effective. Compared to TZD add-on to MET plus SU, 
the triple therapy with SAXA reached an incremental cost-effectiveness ratio of € 2,610 
per QALY gained. ConClusions: Saxagliptin was predicted to be a cost-effective 
option in Spain when a new drug needs to be added in T2DM patients inadequately 
controlled with metformin and sulphonylurea alone.
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objeCtives: To assess the cost-effectiveness of dapagliflozin, a sodium-glucose 
co-transporter-2 (SGLT-2) inhibitor versus dipeptidyl peptidase-4 inhibitor (DPP4i) 
both added on top of insulin, or compared to insulin alone (±oral anti-diabetes 
agents) for patients who are inadequately controlled on insulin strategy. Methods: 
The CARDIFF diabetes model was used. Clinical inputs were derived from a rand-
omized clinical trial comparing dapagliflozin add-on to insulin with insulin alone, 
and network-meta-analysis for the comparison with DPP4i. Together with United 
Kingdom Prospective Diabetes Study (UKPDS) equations, the model predicts disease 
progression and the number of micro- and macro-vascular complications, along 
with diabetes-specific and all-cause mortality. The perspective of the Spanish health 
care payer was adopted over a lifetime horizon. Costs and utilities were assigned 
to the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and total costs. Deterministic and probabilistic sensitivity analyses were 
conducted. Results: Compared to insulin alone, dapagliflozin added to insulin was 
associated with 0.698 incremental QALYs (95%CI: 0.442; 1.211) at an additional cost 
of € 1,508 (95%CI: € 611; € 1,517), resulting in an incremental cost-effectiveness ratio 
(ICER) point estimate of € 2,159/QALY. Dapagliflozin was found to dominate DPP4i 
add-on to insulin, being associated with slightly less costs (-€ 51; 95%CI: -€ 913; € 553) 
and higher QALYs (0.168; 95%CI: -0.007; 0.417). At a willingness-to-pay threshold of 
€ 20,000/QALY, the dapagliflozin strategy was estimated to have a 100% probability 
of being cost-effective when compared to the insulin alone, and a 98% probability 
when compared to the DPP4i strategy. These findings were shown to be robust to 
variation in range of model parameters. ConClusions: Dapagliflozin added on 
top of Insulin was predicted to be a cost-effective (vs. insulin alone) and cost sav-
ing (vs DPP4i) alternative in Spain in combination with insulin for patients who are 
inadequately controlled with insulin treatment regimens.
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objeCtives: Tolvaptan is a selective vasopressin V2-receptor antagonist indicated 
for the treatment of adult patients with hyponatraemia (HN) secondary to syndrome 
of inappropriate antidiuretic hormone secretion (SIADH). To date there have been 
no published economic evaluations assessing the cost effectiveness of tolvaptan 
in this indication. The aim of this study was to evaluate the cost effectiveness 
of tolvaptan versus no active treatment (NAT) from a Swedish societal perspec-
tive. Methods: The economic evaluation considers a hypothetical population of 
individuals with HN secondary to SIADH who have either failed to respond to fluid 
restriction or for whom the use of fluid restriction is not suitable. The analysis con-
siders three clinically relevant patient populations within the SIADH indication: ‘all 
SIADH’, small-cell lung cancer (SCLC) and pneumonia. A discrete event simulation 
was developed to model the progression of individuals through multiple inpatient 
admissions over a 30 day time horizon (180 days in the SCLC scenario). Key sources 
of evidence included randomised controlled trials (SALT I & II) and observational 
data sources. Unit costs were collected from publicly available sources. Utility values 
were obtained from mapping the SF-12 scores from the SALT I & II trials to EQ-5D. 
The primary outcome of the analysis was the incremental cost-effectiveness ratio 
(ICER) expressed as a cost per quality-adjusted life-year (QALY). Results: In the 
‘all SIADH’ population tolvaptan was associated with reduced costs (SEK 5,778) and 
increased QALYs (0.0019) versus NAT and was therefore dominant. In the SCLC and 
pneumonia subgroups tolvaptan was also associated with reduced costs and QALY 
improvements. The results were most sensitive to the duration of tolvaptan treat-
ment and the assumptions around duration of hospitalisation. ConClusions: In 
all populations considered (all SIADH, SCLC and pneumonia) tolvaptan was domi-
nant compared to NAT being associated with reduced costs and increased QALYs.
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objeCtives: To assess the cost-effectiveness of the novel SGLT2is empagliflozin 10mg 
and 25mg compared to other SGLT2is (canagliflozin 100mg, canagliflozin 300mg, and 
dapagliflozin 10mg) when administered as an add-on to metformin for the treat-
ment of patients with T2DM in the UK. Methods: A micro-simulation model was 
developed, based on the United Kingdom Prospective Diabetes Study (UKPDS68) and 
the Januvia Diabetes Economic (JADE) model, to estimate long-term diabetes-related 
complications, QALYs and costs in a cohort of T2DM patients initiating dual therapy. 
The model was populated with the results of a network meta-analysis that estimated 
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objeCtives: To evaluate the economic burden among patients diagnosed with 
Cushing’s disease (CD) in the U.S. Medicaid program. Methods: Patients diagnosed 
with CD (International Classification of Disease, 9thRevision, Clinical Modification 
(ICD-9-CM) diagnosis code 255.0) were identified using U.S. Medicaid data from 01 
January 2008 through 31 December 2010. The initial diagnosis date was designated 
as the index date. A matching comparator cohort was created including patients of 
the same age, race and gender but without a CD diagnosis, and a randomly-chosen 
index date to minimize selection bias. Patients in both cohorts were required to be 
age ≥ 18 years, with continuous medical and pharmacy benefits for 1 year pre- and 
1 year post-index date. One-to-one propensity score matching (PSM) was used to 
compare health care costs and utilizations during the follow-up period between the 
diseased and comparison cohorts, and was adjusted for baseline demographic and 
clinical characteristics. Results: After risk adjustment by PSM, a total of 340 patients 
in each cohort were matched. CD patients had significantly higher health care utili-
zation, including inpatient admissions (36.18% vs. 12.53%, p< 0.0001) and long-term 
care (5.29% vs. 2.06%, p< 0.05), other service (100% vs. 94.12%, p< 0.0001) and pharmacy 
visits (84.41% vs. 78.24%, p< 0.05), compared to those without the disease. CD patients 
incurred significantly higher inpatient ($4,688 vs. $1,139, p< 0.05) and pharmacy costs 
($4,054 vs. $2,100, p< 0.001) compared to those without CD. Long-term care and other 
service costs incurred were higher for CD patients, compared to comparison patients, 
but were not statistically significant. ConClusions: In the current study, CD patients 
in the U.S. Medicaid program had a higher burden of illness in terms of health care 
resource utilization and costs, compared to those without a CD diagnosis.
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objeCtives: The Dose Adjustment For Normal Eating (DAFNE) structured education 
programme is shown to be effective both in terms of clinical outcomes and cost-
effectiveness outcomes in the treatment of T1DM. DAFNEPlus aims to revise the 
DAFNE 5-day curriculum based on psychological and sociological findings in DAFNE, 
input from DAFNE graduates and emerging knowledge around behavioural science 
and technological developments. The current suggested primary endpoint is for the 
DAFNEplus programme to have an additional 20% DAFNE participants (70% in total) 
achieve either, (a) a reduction of at least 0.5% in HbA1c, or (b) to have an HbA1c below 
7.5% (58.5 mmol/mol), at 12 months. This paper undertakes pre-trial what-if cost-
effectiveness analyses concerning the DAFNEPlus programme, which aim to be use-
ful both in the design of the intervention itself and of the proposed trial. Methods: 
The Sheffield Type 1 Diabetes Policy Model is an individual patient-level simulation 
model of T1DM. It includes long-term microvascular (retinopathy, neuropathy and 
nephropathy) and macrovascular (myocardial infarction, stroke, revascularization 
and angina) diabetes-related complications and acute adverse events (severe hypo-
glycaemia and diabetic ketoacidosis). Econometric methods were used to obtain 
the target level of HbA1c responders in the DAFNEPlus arm. Results: DAFNEplus 
would be considered as cost-effective if the additional spending on the intervention 
would be limited to £455-£751 per patient per year, depending on the assumptions 
on the length of maintenance period for the HbA1c benefit and the target HbA1c 
responder endpoint (70% in total) being achieved in the future trial. To achieve a 
more favourable cost-effectiveness probability of 80%, for example, the additional 
per patient per year cost should be restricted to £393-£574 range. ConClusions: 
Pre-trial modelling has enabled a clear understanding of the threshold range for the 
annual cost of DAFNEplus, which is still being designed, in order to be considered 
as cost-effective at the £20,000/QALY threshold.
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objeCtives: In patients with type 2 diabetes mellitus (T2DM), when blood glucose 
is not adequately controlled by the combination of metformin (MET) and sulphony-
lurea (SU), the clinician has to choose between adding a third oral drug or starting 
insulin therapy. The objective of this study was to assess the cost-effectiveness in the 
Spanish setting of adding saxagliptin (SAXA) to MET and SU, compared to adding basal 
insulin (INS). Additionally, the SAXA strategy was compared with a thiazolidinedione 
(TZD), also added on top of MET and SU. Methods: The published and validated 
CARDIFF long-term diabetes model was used to estimate the direct medical costs and 
quality-adjusted life years (QALYs) associated with each strategy. Clinical inputs were 
obtained from a network meta-analysis. Based on the United Kingdom Prospective 
Diabetes Study equations, the model predicted disease progression and occurrence 
of micro- and macro-vascular complications, including mortality. Costs and utilities 
were applied to complications, hypoglycaemias and body mass index changes. The 
perspective of the Spanish Healthcare System was adopted over a lifetime horizon, 
at a discount rate of 3% (costs and health outcomes). Univariate and probabilistic 
sensitivity analyses were conducted. Results: SAXA add-on to MET plus SU resulted 
in a dominant strategy compared to INS add-on to MET plus SU, providing a gain of 
